Asset management firms US West Coast and BHR Partners led a $60m Series D funding round in Insilico Medicine, a clinical-stage end-to-end artificial intelligence-driven drug discovery company, with participation from Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. "It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners, and produced our first novel antifibrotic program discovered using AI and aging research, and designed using our generative AI chemistry engine. This unique program completed a first-in-human Phase 0 study in healthy volunteers and has entered Phase I clinical trials. We have also nominated seven preclinical candidates across a number of other disease indications since 2021. I am very excited about this progress and have decided to personally invest in this round," Alex Zhavoronkov, Insilico Medicine Founder and CEO.